Novo Stock Is Down More Than 70% From Its Peak. Value Trap or Generational Buying Opportunity?

Novo Nordisk has a huge opportunity in GLP-1 weight-loss drugs, but it has to prove it can use that success to build for the future.

CryptoAlerta — análise de criptomoedas e mercado em tempo real